IN VITRO – IN VIVO CORRELATION FOR GLICLAZIDE 60 MG MODIFIED RELEASE TABLETS
DOI:
https://doi.org/10.24193/subbchem.2019.2.18Keywords:
gliclazide, in vitro-in vivo correlations, clinical trial, healthy Caucasian subjectsAbstract
The objective of the study was to determine in vitro – in vivo correlations for Gliclazide 60 mg modified release tablets developed by Ranbaxy Laboratories Limited, now Sun Pharmaceutical Industries Limited, India, based on the data obtained in two bioequivalence clinical trials and in in vitro dissolution tests. Each clinical trial was designed as an open-label, randomized, single-dose, crossover study that consisted of two periods. The first bioequivalence study was performed under the fasting state of the subjects, while the second bioequivalence study was carried out under the fed state of the subjects. During each study period, venous blood samples were taken pre-dose and post-dose up to 96 hours. Afterwards, individual plasma profiles were obtained and mathematical deconvolution was applied to obtain the relative fraction absorbed of gliclazide. These data were correlated with the in vitro dissolution data obtained after performing dissolution tests in three different dissolution media, at pH 4.5, 6.8 and 7.2, with Gliclazide 60 mg modified release tablets (EvoluPharm, France). All calculation were performed by Phoenix WinNonlin® version 6.3. For each in vivo data set from the bioequivalence studies (under fasting and fed conditions), three level A in vitro-in vivo correlations were obtained for Gliclazide 60 mg modified release tablets, for in vitro tests performed at pH 4.5, 6.8, and 7.2. Good correlation coefficients were found for each established correlation (R2=0.98-0.99). In conclusion, six level A in vitro-in vivo correlations were obtained for Gliclazide 60 mg modified release tablets manufactured by Ranbaxy Laboratories Limited, now Sun Pharmaceutical Industries Limited, India.
References
G.L. Amidon, H. Lennernas, V.P. Shah, J.R. Crison, Pharmaceutical Research, 1995, 12(3), 413.
B.M. Davit, I. Kanfer, Y.C. Tsang, J.M. Cardot, The AAPS Journal, 2016, 18(3), 612.
L. Shargel, A.B.C. Yu, "Applied biopharmaceutics and pharmacokinetics, 7th edition", McGraw-Hill Education, Inc., Maryland, 2016, chapter 15.
International Council for Harmonization of technical; requirements for pharmaceuticals for human use. Biopharmaceutics classification system-based biowaivers. 2018. Available at: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M9/M9EWG_DraftGuideline_Step2_2018_0606.pdf. Accessed January 10, 2019.
J.E. Polli, The AAPS Journal, 2008, 10(2), 289.
S. Grbic, J. Parojcic, S. Ibric, Z. Djuric, AAPS PharmSciTech, 2011, 12(1), 165.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. 1997. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm070239.pdf. Accessed January 10, 2019.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. SUPAC-MR: Modified Release Solid Oral Dosage Forms. 1997. Available at: https://www.fda.gov/downloads/Drugs/Guidances/ucm070640.pdf. Accessed January 10, 2019.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. 2017. Available at: https://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf. Accessed January 10, 2019.
L.X. Yu, G.L. Amidon, J.E. Polli et al., Pharmaceutical Research, 2002, 19(7), 921.
D.I. Pop, A.M. Gheldiu, M. Oroian, A. Marcovici, S. Bhardwaj, A. Khuroo, R. Kochhar, L. Vlase, Acta Medica Marisiensis, 2018, 64(4), 161.
M.B.V. Priya, T.E.G.K. Murthy, Dissolution Technologies, May 2012, 38.
K.K.S. Skripnik, M.K. Riekes, B.R. Pezzini, S.G. Cardoso, H.K. Stulzer, AAPS PharmSciTech, 2017, 18(5), 1785.
D.I. Pop, M. Oroian, S. Bhardwaj, A. Marcovici, A. Khuroo, R. Kochhar, L. Vlase, Clinical Pharmacology in Drug Development, 2019, 8(1), 16.
D.I. Pop, M. Oroian, S. Bhardwaj, A. Marcovici, A. Khuroo, R. Kochhar, L. Vlase, Farmacia, 2018, 66(4), 597.
The United States Pharmacopeia, 23rd edition. "In Vitro and In Vivo Evaluation of Dosage form < 1088>". Rockville, Maryland, 1995, 1824.
J.M. Cardot, B.M. Davit, The AAPS Journal, 2012, 14(3), 491.
A. Sarkar, A. Tiwari, P.S. Bhasin, M. Mitra, Journal of Applied Pharmaceutical Science, 2011, 01(09), 11.
Summary of product characteristics Gliclazida® Terapia 60 mg. Available at: https://www.anm.ro/_/_RCP/RCP_8149_30.09.15.pdf. Accessed January 10, 2019.
Product information Diamicron® MR 30 mg. Available at https://www.medicines.org.uk/emc/product/1321/smpc. Accessed January 10, 2019.
A Gumieniczek, A Berecka, R Pietras, M Slebioda, Cent Eur J Chem, 2014, 12(1), 80.
Chemical structure of gliclazide, available at: https://pubchem.ncbi.nlm.nih.gov/compound/gliclazide#section=2D-Structure. Accessed on the 22nd of May 2019.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Studia Universitatis Babeș-Bolyai Chemia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
